Designer drug analogues are synthetic or laboratory-prepared structural or functional analogues of substances controlled under national law or international conventions, designed to reproduce the pharmacological effects of a parent drug while circumventing legal control and standard detection ^[1]. The defining operational logic is deliberate molecular modification: a known psychoactive scaffold is chemically altered—through substitution, chain extension, or ring modification—to generate a compound that retains or exaggerates the biological activity of the parent substance but falls outside existing scheduling provisions ^[2][3]. Drug analogues are formally classifiable into direct analogues, sharing both chemical and pharmacological similarity with the original; structural analogues, sharing structural features only; and functional analogues, chemically different compounds that display similar pharmacological properties ^[4]. Contemporary designer drug analogues are organized by chemical scaffold rather than by pharmacological effect, and the principal classes include synthetic cannabinoid receptor agonists, synthetic cathinones, fentanyl and other novel synthetic opioids, phenethylamines, tryptamines, designer benzodiazepines, and dissociative agents ^[2][5]. Because the analogue is produced by clandestine synthesis rather than pharmaceutical development, its identity and purity are not controlled, and the structural modification that confers legal invisibility may simultaneously increase potency or introduce uncharacterized toxicity ^[3][5].